These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 10465180)
21. Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review. Maguire MJ; Hemming K; Wild JM; Hutton JL; Marson AG Epilepsia; 2010 Dec; 51(12):2423-31. PubMed ID: 21070215 [TBL] [Abstract][Full Text] [Related]
22. Severe persistent visual field constriction associated with vigabatrin. Chronic refractory epilepsy may have role in causing these unusual lesions. Wilson EA; Brodie MJ BMJ; 1997 Jun; 314(7095):1693. PubMed ID: 9193311 [No Abstract] [Full Text] [Related]
23. Vigabatrin as first add-on treatment in carbamazepine-resistant epilepsy patients. Murri L; Iudice A Acta Neurol Scand Suppl; 1995; 162():40-2. PubMed ID: 7495189 [TBL] [Abstract][Full Text] [Related]
24. No reversion in vigabatrin-associated visual field defects. Nousiainen I; Mäntyjärvi M; Kälviäinen R Neurology; 2001 Nov; 57(10):1916-7. PubMed ID: 11723291 [TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group. Chadwick D Lancet; 1999 Jul; 354(9172):13-9. PubMed ID: 10406359 [TBL] [Abstract][Full Text] [Related]
26. Open comparative long-term study of vigabatrin vs carbamazepine in newly diagnosed partial seizures in children. Zamponi N; Cardinali C Arch Neurol; 1999 May; 56(5):605-7. PubMed ID: 10328256 [TBL] [Abstract][Full Text] [Related]
28. Visual field defects associated with vigabratin monotherapy in children. Luchetti A; Amadi A; Gobbi G J Neurol Neurosurg Psychiatry; 2000 Oct; 69(4):566. PubMed ID: 11183043 [No Abstract] [Full Text] [Related]
29. Severe persistent visual field constriction associated with vigabatrin. Four possible explanations exist. Harding GF BMJ; 1997 Jun; 314(7095):1694. PubMed ID: 9193314 [No Abstract] [Full Text] [Related]
30. Severe persistent visual field constriction associated with vigabatrin. Manufacturers have started several studies. Backstrom JT; Hinkle RL; Flicker MR BMJ; 1997 Jun; 314(7095):1694-5. PubMed ID: 9193315 [No Abstract] [Full Text] [Related]
31. Severe persistent visual field constriction associated with vigabatrin. Asymptomatic as well as symptomatic defects occur with vigabatrin. Mackenzie R; Klistorner A BMJ; 1998 Jan; 316(7126):233. PubMed ID: 9468717 [No Abstract] [Full Text] [Related]
32. Severe visual-field constriction and side-effects of GABA-mimetic antiepileptic agents. Baulac M; Nordmann JP; Lanoé Y Lancet; 1998 Aug; 352(9127):546. PubMed ID: 9716066 [No Abstract] [Full Text] [Related]
33. [Concentric changes in the visual field associated with GABA-mimetic antiepileptic agents]. Nordmann JP; Baulac M; Van Egroo C J Fr Ophtalmol; 1999 May; 22(4):418-22. PubMed ID: 10365327 [TBL] [Abstract][Full Text] [Related]
34. Severe persistent visual field constriction associated with vigabatrin. Eke T; Talbot JF; Lawden MC BMJ; 1997 Jan; 314(7075):180-1. PubMed ID: 9022432 [No Abstract] [Full Text] [Related]
35. New antiepileptic drugs for children: felbamate, gabapentin, lamotrigine, and vigabatrin. Devinsky O; Vazquez B; Luciano D J Child Neurol; 1994 Oct; 9 Suppl 1():S33-45. PubMed ID: 7822751 [TBL] [Abstract][Full Text] [Related]
36. Full-field ERG and visual fields in patients 5 years after discontinuing vigabatrin therapy. Kjellström U; Lövestam-Adrian M; Andréasson S; Ponjavic V Doc Ophthalmol; 2008 Sep; 117(2):93-101. PubMed ID: 18188629 [TBL] [Abstract][Full Text] [Related]
37. [The function of eye and vision system in children and youth treated with vigabatrin--our own experiences]. Pojda-Wilczek D; Emich-Widera E; Herba E; Pojda SM; Marszał E Klin Oczna; 2005; 107(10-12):654-7. PubMed ID: 16619812 [TBL] [Abstract][Full Text] [Related]
38. Severe persistent visual field constriction associated with vigabatrin. Reaction might be dose dependent. Wong IC; Mawer GE; Sander JW BMJ; 1997 Jun; 314(7095):1693-4. PubMed ID: 9193312 [No Abstract] [Full Text] [Related]